VR Logo

Glenmark Pharmaceuticals Ltd.


Healthcare | Drugs & Pharma

we think vacations are for wimps

39 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Manufacture of allopathic pharmaceutical preparations

Incorporated: 1977

Chairman: Glenn Saldanha

Managing Director: Glenn Saldanha

Group: Glenmark

Listing: NSE: GLENMARK, BSE: 532296

Headquarters: Mumbai, Maharashtra

Website: www.glenmarkpharma.com

Key Facts

Market cap: R 10,014.15 Cr

Revenue (TTM): R 10,436.95 Cr

Earnings (TTM): R 717.32 Cr

Cash: R 937.77 Cr

Total Debt: R 4,448.67 Cr

Promoters' ownership: 46.62%

Liquidity: High

52 Week range: R 161.65 - 560.00

Face value: R1.00

Shares outstanding: 28,21,68,156

10 Years Aggregate:

  • CFO: 3,60,094.90 Cr
  • EBITDA: 11,921.58 Cr
  • Net Profit: 6,217.20 Cr

Stock Performance

Time Period Glenmark Pharma. S&P BSE Healthcare S&P BSE Mid Cap
YTD2.1916.51-20.88
1 month7.692.05-1.42
3 months27.9216.07-18.88
1 Year-34.8117.60-21.55
3 Years-16.514.88-6.80
5 Years-16.50-1.532.02
10 Years2.7511.045.65
As on 29-May-2020
Year Glenmark Pharma. S&P BSE Mid Cap S&P BSE Healthcare
2019-49.80-3.05-3.55
201816.43-13.31-5.89
2017-33.0648.130.49
2016-3.827.97-12.88
201518.887.4315.06
201445.2754.6947.43
2013-0.89-5.7322.55